HC Wainwright Has Optimistic Outlook of DBVT Q2 Earnings

Key Points

• HC Wainwright raised its Q2 2026 EPS estimate for DBV to ($0.12) from ($0.13) and provided a multi-year earnings outlook forecasting FY2026 ($0.35), FY2027 ($0.21), FY2028 $0.38 and FY2030 $1.45 per share.
• DBV reported Q1 EPS of ($0.56) on April 30, missing the consensus ($0.14) by $0.42, with revenue of $0.90M versus estimated $1.11M and very large negative margins and return on equity.
• Analysts remain generally positive—MarketBeat shows a consensus rating of Moderate Buy with a $40.25 target and several firms have raised targets (e.g., Citizens Jmp $55, Guggenheim $51); the stock trades near $19.47 with a ~$1.08B market cap.

DBV Technologies S.A. (NASDAQ:DBVT - Free Report) - Investment analysts at HC Wainwright lifted their Q2 2026 earnings per share estimates for shares of DBV Technologies in a research report issued on Friday, May 1st. HC Wainwright analyst A. Fein now forecasts that the company will post earnings per share of ($0.12) for the quarter, up from their previous forecast of ($0.13). The consensus estimate for DBV Technologies' current full-year earnings is ($0.82) per share. HC Wainwright also issued estimates for DBV Technologies' FY2026 earnings at ($0.35) EPS, FY2027 earnings at ($0.21) EPS, FY2028 earnings at $0.38 EPS and FY2030 earnings at $1.45 EPS.

Several other brokerages also recently commented on DBVT. Wall Street Zen upgraded DBV Technologies from a "sell" rating to a "hold" rating in a research note on Saturday. Citizens Jmp raised their target price on DBV Technologies from $47.00 to $55.00 and gave the company a "market outperform" rating in a research note on Friday. Guggenheim restated a "buy" rating and issued a $51.00 target price on shares of DBV Technologies in a research note on Monday. Finally, Citigroup reiterated an "outperform" rating on shares of DBV Technologies in a research note on Friday. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, DBV Technologies currently has a consensus rating of "Moderate Buy" and a consensus price target of $40.25.

DBV Technologies Price Performance

Shares of DBVT opened at $19.47 on Tuesday. The stock has a 50-day moving average of $20.89 and a 200-day moving average of $18.89. The company has a market cap of $1.08 billion, a PE ratio of -4.37 and a beta of -0.97. DBV Technologies has a one year low of $7.53 and a one year high of $26.18.

DBV Technologies (NASDAQ:DBVT - Get Free Report) last issued its earnings results on Thursday, April 30th. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.42). The firm had revenue of $0.90 million during the quarter, compared to analyst estimates of $1.11 million. DBV Technologies had a negative net margin of 2,895.37% and a negative return on equity of 129.88%.

Hedge Funds Weigh In On DBV Technologies

A number of hedge funds have recently added to or reduced their stakes in the stock. Diversify Wealth Management LLC acquired a new position in DBV Technologies during the 1st quarter valued at about $1,293,000. Personal CFO Solutions LLC acquired a new position in DBV Technologies during the 1st quarter valued at about $264,000. AdvisorShares Investments LLC acquired a new position in DBV Technologies during the 1st quarter valued at about $1,052,000. Ikarian Capital LLC acquired a new position in DBV Technologies during the 4th quarter valued at about $10,064,000. Finally, Vestal Point Capital LP acquired a new position in DBV Technologies during the 4th quarter valued at about $5,751,000. Institutional investors and hedge funds own 71.74% of the company's stock.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.